Korean J Gastroenterol.  2015 Mar;65(3):159-164. 10.4166/kjg.2015.65.3.159.

Ideal Vaccination Strategy in Inflammatory Bowel Disease

Affiliations
  • 1Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea. cklee92@paran.com

Abstract

Inflammatory bowel disease (IBD) is a long-standing disease that often requires long-term use of immunosuppressive agents including immunomodulators (such as azathioprine, 6-mercaptopurine and methotrexate) and tumor necrosis factor-alpha inhibitors (such as infliximab and adalimumab). Introduction of immunosuppressive therapies, however, involves the risk of host susceptibility to opportunistic infections in this patient population. Therefore, adequate immunization for vaccine-preventable infectious diseases is currently recommended for all patients with IBD and is emerging as an important target for quality improvements in IBD care. However, ongoing issues regarding underuse of immunization, safety and efficacy of vaccines in patients with IBD remain. For quality improvements in IBD care, all physicians should follow the recent immunization guidelines proposed by professional IBD societies. Additionally, there are ongoing needs for intensive educational programs regarding a role of immunization in long-term care of IBD and up-to-date immunization guidelines. Immunization status should be checked at the time of diagnosis of IBD and timely vaccination before initiation of immunosuppressive therapies can be a practical solution for maximizing the efficacy of vaccination at this point. Inactivated vaccines can be used safely irrespective of immunization status of patients, while attenuated vaccines are contraindicated in patients on immunosuppressive therapies. This article reviews an ideal strategy for vaccinating patients with IBD based on the currently recommended immunization guidelines.

Keyword

Vaccination; Inflammatory bowel diseases; Immunosuppressive agents; Tumor necrosis factor-alpha inhibitor

MeSH Terms

Antibodies, Monoclonal/therapeutic use
Humans
Immunosuppressive Agents/therapeutic use
Inflammatory Bowel Diseases/diagnosis/drug therapy/*immunology
Influenza Vaccines/immunology
Influenza, Human/prevention & control
Pneumonia/prevention & control
*Vaccination
Vaccines, Synthetic/immunology
Antibodies, Monoclonal
Immunosuppressive Agents
Influenza Vaccines
Vaccines, Synthetic

Figure

  • Fig. 1. Vaccination strategy in patients with inflammatory bowel disease. IBD, inflammatory bowel disease; TNF, tumor necrosis factor; MMR, measles, mumps, rubella; DTP, diphtheria, tetanus, pertussis; TIV, trivalent influenza vaccine; PCV13, pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.


Reference

References

1. Dignass A, Van Assche G, Lindsay JO, et al. European Crohn's and Colitis Organisation (ECCO). The second European evi-dence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010; 4:28–62.
Article
2. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009; 104:465–483.
Article
3. D'Haens G, Baert F, van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open rand-omised trial. Lancet. 2008; 371:660–667.
4. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362:1383–1395.
Article
5. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010; 59:1200–1206.
Article
6. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppre-ssants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54:237–241.
Article
7. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134:929–936.
Article
8. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT TM registry. Am J Gastroenterol. 2012; 107:1409–1422.
9. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013; 108:1268–1276.
Article
10. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10:677–692.
Article
11. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009; 15:1410–1416.
Article
12. AGA quality and outcomes measures. [Internet]. Bethesda (MD): American Gastroenterological Association [updated 2012 Jun; cited 2015 Mar 9]. Available from:. http://www.gastro.org/practice/quality-initiatives/performance-measures/aga-quality-and-outcomes-measures.
13. Melmed GY, Siegel CA. Quality improvement in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013; 9:286–292.
14. Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013; 19:662–668.
15. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006; 101:1834–1840.
Article
16. Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011; 17:2536–2540.
Article
17. Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 2012; 18:34–40.
Article
18. Yun HS, Min YW, Chang DK, et al. Factors associated with vaccination among inflammatory bowel disease patients in Korea. Korean J Gastroenterol. 2013; 61:203–208.
Article
19. Kim SB, Park SJ, Chung SH, et al. Vaccination and comple-mentary and alternative medicine in patients with inflammatory bowel disease. Intest Res. 2014; 12:124–130.
Article
20. Jung YS, Park JH, Kim HJ, et al. Insufficient knowledge of korean gastroenterologists regarding the vaccination of patients with inflammatory bowel disease. Gut Liver. 2014; 8:242–247.
Article
21. Carrera E, Manzano R, Garrido E. Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol. 2013; 19:1349–1353.
Article
22. Rahier JF, Papay P, Salleron J, et al. European Crohn's and Colitis Organisation (ECCO). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011; 60:456–462.
Article
23. Cullen G, Bader C, Korzenik JR, Sands BE. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012; 61:385–391.
Article
24. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2013∗. Ann Intern Med. 2013; 158:191–199.
25. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58:309–318.
Article
26. Dezfoli S, Melmed GY. Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression. Gastroenterol Hepatol (N Y). 2012; 8:504–512.
27. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105:148–154.
Article
28. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012; 18:1042–1047.
Article
29. Lee CK, Kim HS, Ye BD, et al. Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis. 2014; 8:384–391.
Article
30. Abdallah J, Anna K, Hassan T, Jain A. Vaccination outcomes in inflammatory bowel disease (abstract). Gastroenterology. 2014; 146(Suppl 1):S170.
31. Recommended immunization schedule for adults in Korea, by the Korean Society of Infectious Diseases, 2012. Clin Exp Vaccine Res. 2014; 3:110–112.
32. Park SH, Yang SK, Park SK, et al. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20:69–74.
Article
33. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008; 103:631–636.
Article
34. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009; 136:451–458.
Article
35. Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis. 2009; 15:1621–1629.
Article
36. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57:1–30.
37. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4:1483–1490.
Article
38. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010; 4:603–605.
Article
39. Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol. 2011; 65:870.
Article
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr